Conexeu Sciences
Reno, Nevada, United States · Biotechnology · 9 employees
Conexeu Sciences is a biotechnology company advancing regenerative medicine with its patented collagen flowable gel platform. Emerging from over a decade of University research, Conexeu is developing this groundbreaking technology that could transform wound care, medical aesthetics, and tissue engineering. The company holds patents in the U.S., E.U., Japan, Australia, and pending in Canada, unders
Funding history
- Series pre-seed — $203 — Jun 2026
- Series pre-seed — $86K — Jun 2026
- Series pre-seed — $23K — Jun 2026
- Series pre-seed — $543 — May 2026
- Series pre-seed — $45K — May 2026
Recent signals
- Jun 30, 2026: Raised $203 in Series pre-seed
- Jun 30, 2026: Raised $86K in Series pre-seed
- Jun 16, 2026: Conexeu Sciences Inc. Promotes David Bogart to Chief Commercial Officer
- Jun 10, 2026: Raised $23K in Series pre-seed
- May 21, 2026: Raised $543 in Series pre-seed
- May 21, 2026: Raised $45K in Series pre-seed
- May 11, 2026: SEC 8-K (3.02): On May 12, 2026, Conexeu Sciences Inc. executed an unregistered sale of equity securities through the exercise of common stock purchase warrants, resulting in the issuance of 4,342,648 shares of common stock. The gross proceeds from this transaction amounted to approximately $1,963,967, with the funds intended for general working capital purposes. The warrants were exercised at various prices, with the majority at $0.40 per share, leading to significant capital infusion for the company. This event may enhance the company's liquidity and support its ongoing operations.
- Apr 01, 2026: Raised $1.8M in Series seed
See plans & pricing → Track Conexeu Sciences’s funding, hiring, and signals — with verified contacts — on Fundz.